Anticoagulation Manager vs AnticoagEvaluator Uso & Estadísticas

The Anticoagulation Manager is a mobile application developed through the collaborative efforts of the CDC and the Georgia Institute of Technology. Since the determination of the correct type and dose of anticoagulant drugs can be challenging, this application is a resource for clinicians to appropriately order laboratory testing and choose anticoagulant drugs for the various indications. It gives clinicians evidence-based, accessible, and accurate information when prescribing anticoagulants to prevent and/or treat abnormal clotting states.
  • App Store de Apple
  • Gratis
  • Medicina

Clasificación de tiendas

- -

Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator. Use the app to: • Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed • Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention • Generate individualized risk for antithrombotic therapy options based on individual clinical trials. • Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics. This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
  • App Store de Apple
  • Gratis
  • Medicina

Clasificación de tiendas

- -

Anticoagulation Manager frente a AnticoagEvaluator: comparación de la clasificación

Comparar la tendencia de clasificación de Anticoagulation Manager en los últimos 28 días con AnticoagEvaluator

Rank

No hay datos disponibles

Comparación de las clasificaciones Anticoagulation Manager frente a AnticoagEvaluator por países

Comparar la tendencia de clasificación de Anticoagulation Manager en los últimos 28 días con AnticoagEvaluator

No hay datos para mostrar

Compara con cualquier sitio gracias a nuestra prueba gratuita

Empieza ya
Anticoagulation Manager VS.
AnticoagEvaluator

23iciembre d, 2024